Dianthus Therapeutics, INC /DE/ Form 4 insider transactions

Dianthus Therapeutics CFO Ryan Savitz exercised stock options and immediately sold 20,000 shares for a significant gain, as part of a pre-arranged trading plan.

Director Jonathan Violin acquired 12,500 stock options in Dianthus Therapeutics on May 22, 2025.

Director Paula Soteropoulos reports acquisition of stock options in Dianthus Therapeutics.

Director Steven J. Romano acquired stock options for 12,500 shares of Dianthus Therapeutics common stock on May 22, 2025.

Director Anne McGeorge acquired stock options for 12,500 shares of Dianthus Therapeutics common stock on May 22, 2025.

Alison Frances Lawton, a director of Dianthus Therapeutics, reported the acquisition of stock options exercisable for 12,500 shares of common stock on May 22, 2025.

Director Simon Read of Dianthus Therapeutics acquires 25,000 stock options at an exercise price of $18.36 on May 22, 2025.

Director Sujay Kango of Dianthus Therapeutics acquired 25,000 stock options on March 4, 2025, according to a Form 4 filing with the SEC.

Edward Carr, Chief Accounting Officer of Dianthus Therapeutics, Inc., was granted stock options for 60,000 shares on February 3, 2025.

Adam M. Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics, reported the acquisition of stock options for 100,000 shares of common stock.

Simrat Randhawa, Chief Medical Officer of Dianthus Therapeutics, reports the acquisition of stock options exercisable for 150,000 shares of common stock.

Ryan Savitz, CFO & CBO of Dianthus Therapeutics, Inc., was granted stock options to purchase 150,000 shares of common stock on February 3, 2025.

Dianthus Therapeutics CEO Marino Garcia was granted stock options to purchase 340,000 shares of common stock on February 3, 2025.

Fairmount Funds Management LLC reports a pro rata distribution of 62,146 common stock shares of Dianthus Therapeutics, Inc. to its membership interest investors on September 27, 2024.

Director Steven J. Romano acquired 22,000 stock options in Dianthus Therapeutics on September 16, 2024, according to a Form 4 filing.

Chief Accounting Officer Edward Carr of Dianthus Therapeutics reports the acquisition of stock options.

Adam Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics, reports the acquisition of stock options.

Simrat Randhawa, Chief Medical Officer of Dianthus Therapeutics, reports the acquisition of stock options.

Ryan Savitz, CFO & CBO of Dianthus Therapeutics, Inc., was granted stock options to purchase 100,000 shares of common stock on May 23, 2024.

Dianthus Therapeutics CEO Marino Garcia was granted stock options to purchase 243,000 shares of common stock on May 23, 2024.

Director Jonathan Violin reports the acquisition of stock options in Dianthus Therapeutics.

Paula Soteropoulos, a director of Dianthus Therapeutics, acquired stock options for 11,000 shares of common stock on May 23, 2024.

Director Leon O. Moulder Jr. reports acquisition of 11,000 stock options in Dianthus Therapeutics.

Director Anne McGeorge acquired 11,000 stock options in Dianthus Therapeutics on May 23, 2024, according to a Form 4 filing.

Alison Frances Lawton, a director of Dianthus Therapeutics, acquired 11,000 stock options on May 23, 2024, at an exercise price of $21.77.

Fairmount Funds Management LLC and Tomas Kiselak report acquisition of stock options in Dianthus Therapeutics, Inc.

Fairmount Funds Management LLC reports the transfer of Dianthus Therapeutics shares from Fairmount Healthcare Fund LP to Fairmount Healthcare Fund II LP as part of the former's wind down.